Oaktree Acquisition Corp. III Life Sciences (OACC): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$422.1K

Year ended 2025-12-31

-$455.7K

Trailing 12 months to 2026-06-30

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$422.1K	n/a	2026-03-26, From 2025-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Blank Checks), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Oaktree Acquisition Corp. III Life Sciences (OACC)	2025-12-31	-$422.1K	n/a
Thayer Ventures Acquisition Corp II (TVAI)	2025-12-31	$617.1K	n/a
Cantor Equity Partners I, Inc. (CEPO)	2025-12-31	$52.6K	n/m
SilverBox Corp IV (SBXDF)	2025-12-31	-$988.4K	n/a
Newbury Street II Acquisition Corp (NTWO)	2025-12-31	-$464.7K	n/a
Translational Development Acquisition Corp. (TDAC)	2025-12-31	-$608.4K	n/m
Globa Terra Acquisition Corp (GTERA)	2025-12-31	-$437.1K	n/a
Copley Acquisition Corp (COPL)	2025-12-31	-$469.0K	n/a
Texas Ventures Acquisition III Corp (TVA)	2025-12-31	-$438.0K	n/a

Compare OACC, TVAI, CEPO, SBXDF side by side · Screen every company in Blank Checks ↗